Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.BGNE · Entity 2168 | CMO, Hematology | December 14, 2021 | December 16, 2021 |
| Prelude Therapeutics IncPRLD · Entity 5561 | President, CMO | October 04, 2025 | October 07, 2025 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date December 14, 2021 · Filed December 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2021-12-14 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rowsRow 2 · 2021-12-14 · Exercise / conversion · Acquired 1,500 · Balance 1,500 F1: Each American Depositary Share represents 13 Ordinary Shares. Row 3 · 2021-12-14 · Sale · Disposed 300 · Balance 1,200 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.27 to $274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 4 · 2021-12-14 · Sale · Disposed 300 · Balance 900 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.57 to $277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 5 · 2021-12-14 · Sale · Disposed 500 · Balance 400 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.78 to $278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 6 · 2021-12-14 · Sale · Disposed 100 · Balance 300 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. Row 7 · 2021-12-14 · Sale · Disposed 200 · Balance 100 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.49 to $281.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 8 · 2021-12-14 · Sale · Disposed 100 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.23 · Expires 2029-06-04 | Direct | 211,276 |
Reported balance
After 2021-12-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-12-14 · Exercise / conversion · Disposed 19,500 · Balance 211,276 F7: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F8: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 160,055 |
Reported balance
Holding disclosure · report date 2021-12-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 160,055 |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.27 to $274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.57 to $277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.78 to $278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.49 to $281.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F7: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
F8: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.
Prelude Therapeutics Inc
Report date October 04, 2025 · Filed October 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,917 |
Ending reported balance
After 2025-10-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-10-04 · Exercise / conversion · Acquired 9,375 · Balance 90,272 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. Row 2 · 2025-10-04 · Tax withholding · Disposed 3,355 · Balance 86,917 F2: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 18,750 |
Reported balance
After 2025-10-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-04 · Exercise / conversion · Disposed 9,375 · Balance 18,750 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F3: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2: Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
F3: The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2021 Filed Sep 3, 2021 00:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 542 | $310.53 | $168,307.26 |
DisclosureSEC source: 0001651308-21-000188 · wf-form4_163062954715699.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a performance-based restricted share unit award previously granted to the Reporting Person. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 00:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 7,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000188 · wf-form4_163062954715699.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,948 F1 · shares: Vesting of a portion of a performance-based restricted share unit award upon satisfaction of performance conditions. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 00:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 542 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000188 · wf-form4_163062954715699.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: Vesting of a portion of a performance-based restricted share unit award upon satisfaction of performance conditions. Read SEC document |
| August 31, 2021 Filed Sep 3, 2021 00:39 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 7,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000188 · wf-form4_163062954715699.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,824 F1 · shares: Vesting of a portion of a performance-based restricted share unit award upon satisfaction of performance conditions. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 68,315 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · derivative · entry 13 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,971 Underlying: Ordinary Shares · 68,315 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F11 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 17, 2021, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 114,803 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · derivative · entry 12 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,776 Underlying: Ordinary Shares · 114,803 shares Expires 2029-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F10 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 89,882 | $0.00 Strike: $12.34 | $0.00 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · derivative · entry 11 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,798 Underlying: Ordinary Shares · 89,882 shares Expires 2028-06-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F9 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 98 | $335.76 | $32,904.48 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · nonDerivative · entry 10 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2020. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,000 | $334.85 | $334,846.00 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · nonDerivative · entry 9 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.41 to $335.22, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,823 | $333.64 | $941,861.49 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · nonDerivative · entry 8 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.17 to $334.10, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 8,177 | $332.71 | $2,720,586.84 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · nonDerivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,921 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.17 to $333.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 6,523 | $331.79 | $2,164,249.86 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,098 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.16 to $332.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,379 | $330.53 | $786,322.31 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,621 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.01 to $330.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 5,255 | $174.43 | $916,629.65 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 8,831 | $119.96 | $1,059,366.76 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 6,914 | $160.40 | $1,109,005.60 |
DisclosureSEC source: 0001651308-21-000154 · wf-form4_162672740353627.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · derivative · entry 10 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,575 Underlying: Ordinary Shares · 19,500 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F10 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $356.98 | $71,395.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 9 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.82 to $357.13, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $355.26 | $106,578.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 8 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.03 to $355.38, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $352.95 | $70,589.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.48 to $353.41, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 400 | $351.06 | $140,425.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.74 to $351.30, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $349.22 | $34,922.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $347.63 | $104,289.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $347.45 to $347.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 20:49 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 1,500 | $29.49 | $44,235.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 20:49 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 425 | $365.00 | $155,125.00 |
DisclosureSEC source: 0001651308-21-000140 · wf-form4_162508617914387.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:45 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 469 | $325.66 | $152,733.04 |
DisclosureSEC source: 0001651308-21-000126 · wf-form4_162430832547020.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share ("ADS") represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:45 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 157,196 | $0.00 Strike: $26.53 | $0.00 |
DisclosureSEC source: 0001651308-21-000126 · wf-form4_162430832547020.xml · derivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,196 Underlying: Ordinary Shares · 157,196 shares Expires 2031-06-15 F4 · derivative.exercise_price: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F4 · shares: The number of securities underlying the option and the exercise price therefor are represented in ordinary shares. F5 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 16, 2022, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:45 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 25,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000126 · wf-form4_162430832547020.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,186 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 01:35 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.51 | $0.00 |
DisclosureSEC source: 0001209191-21-039727 · doc4.xml · derivative · entry 2 Huang Jane · CIK 0001683913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-08 F2 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 01:35 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.51 | $0.00 |
DisclosureSEC source: 0001209191-21-039727 · doc4.xml · derivative · entry 1 Huang Jane · CIK 0001683913 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:45 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 603 | $351.55 | $211,985.55 |
DisclosureSEC source: 0001651308-21-000107 · wf-form4_162327150511384.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2019, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 540 | $362.64 | $195,827.71 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 10 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F8 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a performance-based restricted share unit award previously granted to the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.57 to $362.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| May 31, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantAmerican Depositary Shares | 540 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F1 · shares: Vesting of a portion of a performance-based restricted share unit award upon satisfaction of performance conditions. Read SEC document |
| May 31, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 7,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 1 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,772 F1 · shares: Vesting of a portion of a performance-based restricted share unit award upon satisfaction of performance conditions. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · derivative · entry 11 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,075 Underlying: Ordinary Shares · 19,500 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F11 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $359.42 | $35,942.00 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 9 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 147 | $358.36 | $52,679.46 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 8 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.01 to $358.53, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 353 | $357.50 | $126,196.62 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.93 to $357.81, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $356.21 | $106,863.00 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.85 to $356.41, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 500 | $354.97 | $177,487.00 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.73 to $355.22, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $352.85 | $35,285.00 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 20:40 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 1,500 | $29.49 | $44,235.00 |
DisclosureSEC source: 0001651308-21-000099 · wf-form4_162266637975477.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 19,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · derivative · entry 9 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,575 Underlying: Ordinary Shares · 19,500 shares Expires 2026-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F9 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of September 2, 2016 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. All unvested shares subject to this option are subject to accelerated vesting upon certain termination events. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $358.62 | $71,724.00 |
DisclosureSEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 8 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.55 to $358.69, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $356.25 | $106,875.99 |
DisclosureSEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 7 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.07 to $356.47, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 400 | $355.12 | $142,046.00 |
DisclosureSEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 6 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.74 to $355.49, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $353.94 | $106,182.00 |
DisclosureSEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 5 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.47 to $354.30, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $352.67 | $70,534.00 |
DisclosureSEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 4 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.28 to $353.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $350.25 | $35,025.00 |
DisclosureSEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 3 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019. Read SEC document |
| April 29, 2021 Filed May 3, 2021 20:35 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 1,500 | $29.49 | $44,235.00 |
DisclosureSEC source: 0001651308-21-000078 · wf-form4_162007413043329.xml · nonDerivative · entry 2 Huang Jane · CIK 0001683913 · CMO, Hematology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.